|
Accounting policy Investments in associates, being those entities over which the Group has a significant influence and which is neither a subsidiary nor a joint venture, are accounted for using the equity method, with the Group recording its share of the associates’ profit and loss and other comprehensive income. The Group’s share of associates’ profit or loss is included in one separate income statement line and is calculated after deduction of their respective taxes. |
At 31 December 2017 and 31 December 2016, the Group holds 49% of Bioventus LLC (Bioventus). Bioventus is a limited liability company operating as a partnership. The company’s headquarters is located in Durham, North Carolina, US. Bioventus focuses its medical product development around its core competencies of orthobiologic therapies and orthopaedic diagnostics from which it develops and markets clinically proven orthopaedic therapies and diagnostic tools, including osteoarthritis pain treatments, bone growth stimulators and ultrasound devices. Bioventus sells bone healing stimulation devices and is a provider of osteoarthritis injection therapies. The Group’s ability to recover the value of its investment is dependent upon the ongoing clinical and commercial success of these products. The profit after taxation recognised in the income statement relating to Bioventus was $6m (2016: loss after taxation $3m).
The carrying amount of this investment was reviewed for impairment as at the balance sheet date. For the purposes of impairment testing the recoverable amount of this investment was based on its fair value less cost to sell, estimated using discounted cash flows.
The amounts recognised in the balance sheet and income statement for associates are as follows:
|
|
|
2017 |
|
2016 |
|
|
|
|
$ million |
|
$ million |
|
|
Balance sheet |
|
118 |
|
112 |
|
|
Income statement profit/(loss) |
|
6 |
|
(3) |
|
Summarised financial information for significant associates
Set out below is the summarised financial information for Bioventus, adjusted for differences with Group accounting policies:
|
|
|
2017 |
|
2016 |
|
|
|
|
$ million |
|
$ million |
|
|
Summarised statement of comprehensive income |
|
|
|
|
|
|
Revenue |
|
301 |
|
282 |
|
|
Attributable profit/(loss) for the year |
|
1 |
|
(21) |
|
|
Group adjustments1 |
|
11 |
|
15 |
|
|
Total comprehensive profit/(loss) |
|
12 |
|
(6) |
|
|
Group share of profit/(loss) for the year at 49% |
|
6 |
|
(3) |
|
|
|
|
2017 |
|
2016 |
|
|
|
|
$ million |
|
$ million |
|
|
Summarised balance sheet |
|
|
|
|
|
|
Non-current assets |
|
332 |
|
364 |
|
|
Current assets |
|
122 |
|
105 |
|
|
Non-current liabilities |
|
(246) |
|
(258) |
|
|
Current liabilities |
|
(47) |
|
(53) |
|
|
Net assets |
|
161 |
|
158 |
|
|
Group’s share of net assets at 49% |
|
79 |
|
77 |
|
|
Group adjustments1 |
|
35 |
|
32 |
|
|
Group’s carrying amount of investment at 49% |
|
114 |
|
109 |
|
1 Group adjustments include an adjustment to align the useful life of intangible assets with Group policy.
At December 2017, the Group held an equity investment in one other associate (2016: one) with a carrying value of $3m (2016: $3m).